| Document |
Document Title |
|
WO/2014/104235A1 |
Provided are: an organic electroluminescent element which has high efficiency, can be driven at a low voltage and has a long service life; and a material, particularly an electron-transporting material, which enables the production of th...
|
|
WO/2014/104904A1 |
A process for the preparation of bosentan monohydrate of pharmaceutical purity is characterized by that crude bosentan is suspended in methyl alcohol / dichloromethane mixture at a volume ratio from 8:1 to 1:2, the mixture is stirred at ...
|
|
WO/2014/102233A1 |
The present invention relates to compounds of formula (I), wherein the substituents are described in claim 1 and to the pharmaceutically acceptable salts thereof. These compounds inhibit the enzyme catechol-O-methyltransferase (COMT). Th...
|
|
WO/2014/100767A1 |
The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (J), or pharmaceutically acceptable salts thereof, in which n, m, R1, R2, and R3 are as defined herein. These compounds are useful for treatment o...
|
|
WO/2014/100748A1 |
The present invention provides certain compounds, and compositions thereof, useful as protein kinase inhibitors. In particular, the present invention provides certain 2,4-disubstituted pyrimidine compounds which inhibit activity of one o...
|
|
WO/2014/093230A2 |
The present invention provides novel pyrimidine and pyridine compounds which are attached to a warhead, and the manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic d...
|
|
WO/2014/091167A2 |
The present invention relates to cyclopropylboronic compounds, to the method for preparing same and to the use thereof.
|
|
WO/2014/090700A1 |
The invention relates to the use of a compound of formula (I) or a salt thereof for combating animal pests, where the symbols and indices are defined in the specification.
|
|
WO/2014/093869A1 |
The present technology relates to compounds and compositions of Formulas I-III and methods using such compounds. The compounds and compositions described herein may be used in the treatment or prophylaxis of diseases associated with an a...
|
|
WO/2014/091265A1 |
The present application relates to novel Pyrimidine-2,4-diamine derivatives as kinase inhibitors derivatives of formula (I), as protein kinase inhibitors. Formula (I). The invention particularly relates to compounds of formula (I), prepa...
|
|
WO/2014/092100A1 |
The purpose of the invention is to provide a compound or salt thereof that is useful as an agent for the prevention or treatment of epilepsy, neurodegenerative disease, and the like. The invention pertains to compounds represented by for...
|
|
WO/2014/086738A1 |
The invention relates to 4-amino-6-acyloxymethyl pyrimidine and 4-amino-2-acyloxymethyl pyridine of general formula (I) as herbicides. In this formula (I) R11 to R4 represent groups such as hydrogen, organic groups such as alkyl, and oth...
|
|
WO/2014/087165A1 |
The present invention relates to a compound of formula I wherein X is C(R6) or N, Y is C or N, and ring A, ring B, R1 and R2 have the meanings defined herein, provided that when ring B is carbocyclic, X is C(R6); or a pharmaceutically ac...
|
|
WO/2014/086072A1 |
The present invention belongs to the field of compound preparation. Disclosed are a crystal form of (E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfon
yl)amine]pyrimidine-5-group)(3R,5S)-3,5-dihydroxy-6-heptenoi
c acid ester an...
|
|
WO/2014/082737A1 |
The invention relates to specific carboxamides of formula (I) as KCNQ2/3 modulators, to processes for their preparation, to medicaments comprising these compounds and to the use of these compounds in the preparation of medicaments.
|
|
WO/2014/082739A1 |
The invention relates to amino-arylcarboxamides of formula (I), to pharmaceutical compositions containing these compounds and also to these compounds for use In the treatment and/or prophylaxis of pain and further diseases and/or disorders.
|
|
WO/2014/080341A1 |
The invention relates to a new process for the synthesis of 2-(N-methyl)-amino-4,5,6- trichloro-l,3-pyrimidine, which is more economical than the known process, as well as the new compounds synthesized as intermediates in the process: 2-...
|
|
WO/2014/081752A1 |
Compounds of formula (I) wherein: X is -0-, -S(0)r-, -CH2-, or -NR-, wherein r is 0, 1, or 2; X 1, X2, and X5 are each independently CR7 or N; one of X3 or X4 is C and is attached by a single bond to -L-, and the other is CR7 or N, provi...
|
|
WO/2014/079806A1 |
The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof for use in the treatment or prevention of hairloss, wherein R1, R2, R3, R4, R5 and R6 have one of the meanings as indicated in the spe...
|
|
WO/2014/081619A1 |
The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to th...
|
|
WO/2014/080342A1 |
Our invention relates to trans-(4-{4-[2-(4-amino-cyclohexyl)-ethyl]-piperazin-1-yl}-5
,6- dichloro-pyrimidin-2-yl)-methylamine dihydrochloride monohydrate, the process for the synthesis of this compound, the new (4,5-dichloro-6-piperazin...
|
|
WO/2014/081756A1 |
Compounds of formula (I), and pharmaceutically acceptable salts thereof, can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
|
|
WO/2014/076221A1 |
This invention relates to heterocyclic substituted 2-amino-quinazoline derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.
|
|
WO/2014/075754A1 |
Compounds of the formula (I) in which R1, R4, R, X1, X2, X3, X4, q and W have the meanings indicated in Claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardio...
|
|
WO/2014/076028A1 |
The present invention relates to 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the ...
|
|
WO/2014/078634A1 |
The invention provides novel imidazol-piperidinyl derivatives of formula (I) in which R1, R2, X1, X2, X3, X4 and n have the meanings indicated in above, and their manufacture and use for the treatment of hyperproliferative diseases, such...
|
|
WO/2014/076085A1 |
This invention relates to a novel method for the synthesis of 2,4-dichloro-5-trifluoromethyl- pyrimidine useful as intermediate in the manufacture of pharmaceutically active ingredients.
|
|
WO/2014/072419A1 |
The present invention relates to the field of HIV-1 infections, and in particular provides novel compounds containing fluorine on the Central ring. The compounds according to this invention are very suitable for the prevention and/or tre...
|
|
WO/2014/074906A1 |
Described herein are methods for identifying compounds useful for the treatment of infection by hepatitis B virus (HBV).
|
|
WO/2014/074670A1 |
Compounds having the following formula (I): or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα by acting on Tyk-2 t...
|
|
WO/2014/074775A1 |
The present invention relates to antimalarial compounds and their use against protozoa of the genus Plasmodium, including drug-resistant Plasmodia strains. This invention further relates to compositions containing such compounds and a pr...
|
|
WO/2014/074517A1 |
This disclosure relates to compounds, compositions and methods of epigenetically transforming cells. In certain embodiments, the disclosure relates to methods of generating epigenetically altered cells comprising mixing isolated cells wi...
|
|
WO/2014/072244A1 |
This invention relates to novel sulfoximine substituted quinazoline derivatives of formula (I), wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinas...
|
|
WO/2014/071143A1 |
The invention provides a method for treating prostate cancer in a subject comprising administering to the subject an effective amount of a selective inhibitor of one or more of CDK8 and CDK19. In some embodiments the inhibitor inhibits C...
|
|
WO/2014/068171A1 |
Compounds of formula I or formula II, wherein Q1Q3 and R1-R5 are as defined in the claims, exhibit CytC derived peroxidase inhibiting activity and are thus useful as CytC derived peroxidase inhibiting agents.
|
|
WO/2014/065215A1 |
The present invention addresses the problem of providing: a transparent electrode provided with conductivity and light transmissivity, having low sheet resistance, and exhibiting excellent durability; and an electronic device and an orga...
|
|
WO/2014/063631A1 |
The present invention provides a tyrosine kinase irreversible inhibitor shown in formula I or a pharmaceutically acceptable salt thereof, a preparation method for the tyrosine kinase irreversible inhibitor and applications of the tyrosin...
|
|
WO/2014/063642A1 |
Disclosed is a substituted pyrimidine compound having a structure as represented by formula PY. See the description for the definition of each substituent in the formula. The compound of the present invention provides broad-spectrum bact...
|
|
WO/2014/066772A1 |
This disclosure relates to processes and reagents for making diaryliodonium salts, which are useful for the preparation of fluorinated, iodinated, astatinated and radiofluorinated aromatic compounds.
|
|
WO/2014/064038A1 |
The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula (I) as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are su...
|
|
WO/2014/064058A1 |
The invention discloses improved processes for manufacturing a compound, 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyri
din-2-amine, its monohydrochloride salt and intermediates thereof.
|
|
WO/2014/060376A1 |
The present invention relates to 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amine derivatives of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of...
|
|
WO/2014/060588A1 |
Use of 2,3-dihydroquinazolin-4(lH)-one cyclic derivatives of formula (I) for the treatment of infection with viruses entering cells by endocytosis, especially filovirus such as Ebolavirus.
|
|
WO/2014/062811A2 |
The present invention relates to pharmaceutical compositions comprising a compound and a pharmaceutically acceptable carrier. The present invention is also directed to a method of treating cancer in a subject. Also disclosed are methods ...
|
|
WO/2014/060586A1 |
The present invention concerns a new family of 2,3-dihydroquinazolin-4(1H)-one compounds of general formula (I), and the use thereof as inhibitors of the toxic effects of toxins with intracellular activity, such as ricin or Shiga toxin, ...
|
|
WO/2014/060371A1 |
The present invention relates to the use of novel compounds of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.
|
|
WO/2014/060900A1 |
The present invention provides a process for preparing a compound of formula: (Formula XI and XII) (XI) (XII) wherein X, Y, Z, A, B and E are as defined herein, by reacting a compound of formula: (Formula XIII) (XIII) with a compound of ...
|
|
WO/2014/062044A1 |
Invention is related to novel compounds - fluorinated benzenesulfonamides of general formula (I). The compounds can be used in biomedicine as active ingredients in pharmaceutical formulations, because they inhibit enzymes which participa...
|
|
WO/2014/058747A1 |
Compounds of Formula (I) are HIV reverse transcriptase inhibitors, wherein R1, R2, RE, L, M and Z are defined herein. The compounds of Formula (I) and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse tr...
|
|
WO/2014/057078A1 |
The present application relates to compounds of formula (I), wherein R1 to R5 are as defined in claim 1, a pharmaceutical composition thereof and said compounds for use in the treatment of diseases related with the activity of P2X7 recep...
|
